File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/1749-8546-4-16
- Scopus: eid_2-s2.0-77955773072
- PMID: 19695098
- Find via
Supplementary
-
Bookmarks:
- CiteULike: 2
- Citations:
- Appears in Collections:
Article: Chinese medicines as a resource for liver fibrosis treatment
Title | Chinese medicines as a resource for liver fibrosis treatment |
---|---|
Authors | |
Issue Date | 2009 |
Publisher | BioMed Central Ltd. The Journal's web site is located at http://www.cmjournal.org/home |
Citation | Chinese Medicine, 2009, v. 4, article no. 16 How to Cite? |
Abstract | Liver fibrosis is a condition of abnormal proliferation of connective tissue due to various types of chronic liver injury often caused by viral infection and chemicals. Effective therapies against liver fibrosis are still limited. In this review, we focus on research on Chinese medicines against liver fibrosis in three categories, namely pure compounds, composite formulae and combination treatment using single compounds with composite formulae or conventional medicines. Action mechanisms of the anti-fibrosis Chinese medicines, clinical application, herbal adverse events and quality control are also reviewed. Evidence indicates that some Chinese medicines are clinically effective on liver fibrosis. Strict quality control such as research to identify and monitor the manufacturing of Chinese medicines enables reliable pharmacological, clinical and in-depth mechanism studies. Further experiments and clinical trials should be carried out on the platforms that conform to international standards.© 2009 Feng et al; licensee BioMed Central Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/89655 |
ISSN | 2023 Impact Factor: 5.3 2023 SCImago Journal Rankings: 0.877 |
PubMed Central ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Feng, Y | en_HK |
dc.contributor.author | Cheung, KF | en_HK |
dc.contributor.author | Wang, N | en_HK |
dc.contributor.author | Liu, P | en_HK |
dc.contributor.author | Nagamatsu, T | en_HK |
dc.contributor.author | Tong, Y | en_HK |
dc.date.accessioned | 2010-09-06T09:59:58Z | - |
dc.date.available | 2010-09-06T09:59:58Z | - |
dc.date.issued | 2009 | en_HK |
dc.identifier.citation | Chinese Medicine, 2009, v. 4, article no. 16 | en_HK |
dc.identifier.issn | 1749-8546 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/89655 | - |
dc.description.abstract | Liver fibrosis is a condition of abnormal proliferation of connective tissue due to various types of chronic liver injury often caused by viral infection and chemicals. Effective therapies against liver fibrosis are still limited. In this review, we focus on research on Chinese medicines against liver fibrosis in three categories, namely pure compounds, composite formulae and combination treatment using single compounds with composite formulae or conventional medicines. Action mechanisms of the anti-fibrosis Chinese medicines, clinical application, herbal adverse events and quality control are also reviewed. Evidence indicates that some Chinese medicines are clinically effective on liver fibrosis. Strict quality control such as research to identify and monitor the manufacturing of Chinese medicines enables reliable pharmacological, clinical and in-depth mechanism studies. Further experiments and clinical trials should be carried out on the platforms that conform to international standards.© 2009 Feng et al; licensee BioMed Central Ltd. | en_HK |
dc.language | eng | en_HK |
dc.publisher | BioMed Central Ltd. The Journal's web site is located at http://www.cmjournal.org/home | en_HK |
dc.relation.ispartof | Chinese Medicine | en_HK |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Chinese medicines as a resource for liver fibrosis treatment | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Feng, Y: yfeng@hku.hk | en_HK |
dc.identifier.email | Tong, Y: tongyao@hku.hk | en_HK |
dc.identifier.authority | Feng, Y=rp00466 | en_HK |
dc.identifier.authority | Tong, Y=rp00509 | en_HK |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1186/1749-8546-4-16 | en_HK |
dc.identifier.pmid | 19695098 | - |
dc.identifier.pmcid | PMC3224967 | - |
dc.identifier.scopus | eid_2-s2.0-77955773072 | en_HK |
dc.identifier.hkuros | 166268 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-77955773072&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 4 | en_HK |
dc.identifier.spage | article no. 16 | - |
dc.identifier.epage | article no. 16 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Feng, Y=24467969600 | en_HK |
dc.identifier.scopusauthorid | Cheung, KF=8763216400 | en_HK |
dc.identifier.scopusauthorid | Wang, N=35072317700 | en_HK |
dc.identifier.scopusauthorid | Liu, P=36065603800 | en_HK |
dc.identifier.scopusauthorid | Nagamatsu, T=7006510058 | en_HK |
dc.identifier.scopusauthorid | Tong, Y=9045384000 | en_HK |
dc.identifier.citeulike | 5490239 | - |
dc.identifier.issnl | 1749-8546 | - |